Special Issue "Cancer Molecules in Ovarian Cancer"
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: closed (30 November 2010)
Prof. Dr. Ie-Ming Shih
Department of Pathology, Faculty in Pathobiology PhD Graduate Program, Johns Hopkins University, School of Medicine, CRB-II, Rm 305, 1550 Orleans Street, Baltimore, Maryland 21231, USA
Website | E-Mail
Fax: +1 410 502 7943
Interests: cancer pathogenesis; gene amplification; gene mutation; differential diagnosis; genome-wide analysis of human cancer
Ovarian cancer is a highly aggressive neoplastic disease in women. The molecular etiology of ovarian cancer remains elusive and the attempts to develop effective early detection and treatment for ovarian cancer patients are empirical. Identification and characterization of ovarian cancer-associated genes are fundamental steps toward elucidating its pathogenesis and providing new opportunity for cancer detection and therapy. To this end, many research teams over the past several years have applied several new technologies to study the molecular landscape of ovarian cancer. This special issue timely honors these new advances and cordially invites the publications of new ovarian cancer-associated molecules and the pathways that may shed new light into the pathogenesis of this devastating disease. Specifically, we welcome the manuscripts that report molecules and pathways that i) may be involved in molecular etiology, ii) could be used as potential biomarkers for detections and diagnosis, and iii) may be served as promising molecular targets for new therapeutics in ovarian cancer. Review articles that succinctly summarize recent advances in the fields as mentioned above are also very welcome. Translational research such as applications of markers of ovarian cancer for differential diagnosis and prognostic prediction is also the focus in this special issue.
- ovarian cancer
- target therapy